Zhang Qi, Zhu Bo, Li Yongsheng
Institute of Cancer, Xinqiao Hospital, Third Military Medical University , Chongqing , China.
Front Immunol. 2017 Feb 2;8:71. doi: 10.3389/fimmu.2017.00071. eCollection 2017.
Inflammation is a protective response that eliminates harmful stimuli and restores tissue homeostasis, whereas the failure to resolve inflammation leads to the development of malignancies. Immune cells in the tumor inflammatory microenvironment endow cancer cells with their specific hallmarks, including mutations, metabolic reprograming, angiogenesis, invasion, and metastasis. Targeting the inflammatory microenvironment with anti-inflammatory drugs (e.g., aspirin) or by enhancing antitumor immunity (e.g., chimeric antigen receptor T cell therapy) has been extensively investigated and has achieved promising results in many cancers. Recently, a novel approach promoting antitumor immunity a dual anti-inflammatory and pro-resolving strategy was proposed based on the discovery of potent, endogenous, specialized pro-resolving mediators, including lipoxins, resolvins, protectins, and maresins. In this review, we describe the updated principal cellular and molecular mechanisms of inflammation resolution and cancer immunity and discuss the pro-resolution strategy in cancer treatment and prevention.
炎症是一种保护性反应，可消除有害刺激并恢复组织稳态，而炎症无法消退则会导致恶性肿瘤的发生。肿瘤炎性微环境中的免疫细胞赋予癌细胞特定的特征，包括突变、代谢重编程、血管生成、侵袭和转移。使用抗炎药物（如阿司匹林）或通过增强抗肿瘤免疫力（如嵌合抗原受体T细胞疗法）来靶向炎性微环境已得到广泛研究，并在许多癌症中取得了有希望的结果。最近，基于对强效内源性特异性促炎消退介质（包括脂氧素、消退素、保护素和maresin）的发现，提出了一种促进抗肿瘤免疫的新方法——双重抗炎和促炎消退策略。在这篇综述中，我们描述了炎症消退和癌症免疫的最新主要细胞和分子机制，并讨论了癌症治疗和预防中的促炎消退策略。
